TeklaLife Sciences Investors

Find Ratings Reports
HQL : NYSE :
$20.06 | %
Today's Range: 0.0 - 0.0
Avg. Daily Volume: 0
02/16/18 - 4:02 PM ET
RETURN AND EXPENSE COMPARISON (as of Jan 2017)
HQL Return and Expenses Comparison Chart
1 Month: 1.0% 1 Year: 19.63%
3 Month: 1.74% 3 Year: 0.94%
6 Month: -1.19% 5 Year; 14.86%
Year-to-Date 3.01%    
Last Dividend
(05/30/2017)
$0.41    
Last Cap Gain 0.43    
Expense Ratio 1.32%    
MOST RECENT RATINGS CHANGES
Date Price Action From To
10/31/2017 $20.34 Downgrade HOLD SELL
03/31/2017 $19.39 Upgrade SELL HOLD
06/30/2016 $17.16 Downgrade HOLD SELL
01/31/2016 $18.16 Downgrade BUY HOLD
Sector Allocation
HQL Sector Allocation Chart
Basic Materials0.0%
Capital Goods0.0%
Technology0.0%
Consumer Staples0.0%
Healthcare95.01%
Energy0.0%
Finance2.75%
Transportation0.0%
Communication Services0.0%
Utilities0.0%
Miscellaneous2.24%
RETURN AND VOLATILITY MEASURES
 1 Year3 Year
Alpha26.78%-21.85%
Beta-0.15%1.88%
R-squared0.0%50.0%
Standard Deviation13.96%27.4%
Semi-deviation2.93%6.24%
Definitions:
Alpha - measures the portfolio manager's contribution to performance that is independent of the benchmark.
Beta - measures the portfolio sensitivity to movements in the market relative to the selected underlying benchmark.
R-squared - mesausres how closely the derived forecast was able to explain the performance of the last three years. It also measures diversification with lower number indicating more independence from benchmark.
Standard deviation - measures how closely actual values matched the forecasted values for performance.
Semi-deviation - only considers values that fall below the risk free rate of return.
Top Ten Holdings
Biogen Inc 9.57%
Gilead Sciences Inc 9.39%
Celgene Corp 9.21%
Amgen Inc 8.78%
Vertex Pharmaceuticals Inc 7.61%
Regeneron Pharmaceuticals Inc 6.39%
Incyte Corp 5.98%
Alexion Pharmaceuticals Inc 5.86%
Illumina Inc 3.82%
Biomarin Pharmaceutical Inc 3.46%
 

Latest Stock Upgrades/Downgrades